Marwan Mikheal Azar, MD, FAST, FIDSA
Associate Professor of Medicine (Infectious Diseases) and Laboratory MedicineCards
About
Research
Publications
2024
Successful combination therapy for recurrent refractory cytomegalovirus treatment in a kidney transplant recipient
Marvin J, Trubin P, Azar M. Successful combination therapy for recurrent refractory cytomegalovirus treatment in a kidney transplant recipient. Transplant Infectious Disease 2024, 26: e14329. PMID: 38971997, DOI: 10.1111/tid.14329.Peer-Reviewed Original ResearchA Patient With Type 1 Diabetes and Acute Rhinosinusitis
Roman F, Azar M, Trubin P. A Patient With Type 1 Diabetes and Acute Rhinosinusitis. JAMA 2024, 331: 1586-1587. PMID: 38630502, DOI: 10.1001/jama.2024.0642.Peer-Reviewed Original ResearchAtypical pneumonia testing in transplant recipients
Feller F, Trubin P, Malinis M, Vogel J, Merwede J, Peaper D, Azar M. Atypical pneumonia testing in transplant recipients. Transplant Infectious Disease 2024, 26: e14256. PMID: 38430482, DOI: 10.1111/tid.14256.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationTransplant recipientsPathogens of pneumoniaAtypical pneumoniaAugmented immunosuppressionAtypical pathogensTest positivity rateChimeric antigen receptor T cellsHematopoietic stem cell transplant recipientsDiagnosis of atypical pneumoniaPositive rateCases of mycoplasma infectionStem cell transplantationSolid organ transplantationRetrospective cohort studyMycoplasma infectionImmunocompromised patientsCell transplantationAnalysis of diagnostic testsDiagnostic yieldTransplant cohortPost-transplantationT cellsCohort studyRates of testingLarone’s Medically Important Fungi: A Guide to Identification, 7 Edition - Volume 30, Number 3—March 2024 - Emerging Infectious Diseases journal - CDC
Azar M. Larone’s Medically Important Fungi: A Guide to Identification, 7 Edition - Volume 30, Number 3—March 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 625-626. PMCID: PMC10902529, DOI: 10.3201/eid3003.231623.Peer-Reviewed Original ResearchLung infections due to emerging fungal pathogens
Roman F, Pischel L, Azar M. Lung infections due to emerging fungal pathogens. Current Opinion In Pulmonary Medicine 2024, 30: 258-265. PMID: 38411158, DOI: 10.1097/mcp.0000000000001059.Peer-Reviewed Original ResearchConceptsEndemic mycosesManagement of pulmonary infectionsFungal pathogensPathogenic fungiAntifungal prophylaxisBlastomyces speciesFungal infectionsFungal organismsAspergillus moldsEnvironmental changesImmunocompromised hostsPulmonary infectionTherapeutic challengeLung infectionMycosesClinical evidenceClinical managementIncreased incidencePulmonary diseaseEnlarged poolDisease burdenInfectionLomentosporaScedosporiumDiagnostic capabilitiesClinical outcomes of SARS‐CoV‐2 infection in kidney transplant recipients on belatacept: a single‐center experience
Feller F, Azar M, Marvin J, Cohen E, Virmani S, Malinis M. Clinical outcomes of SARS‐CoV‐2 infection in kidney transplant recipients on belatacept: a single‐center experience. Transplant Infectious Disease 2024, 26: e14253. PMID: 38351494, DOI: 10.1111/tid.14253.Peer-Reviewed Original ResearchThe respiratory syncytial virus vaccines are here: Implications for solid organ transplantation
Trubin P, Azar M, Kotton C. The respiratory syncytial virus vaccines are here: Implications for solid organ transplantation. American Journal Of Transplantation 2024, 24: 897-904. PMID: 38341028, DOI: 10.1016/j.ajt.2024.02.003.Peer-Reviewed Original ResearchRespiratory syncytial virusSolid organ transplantationLower respiratory tract diseaseHigh risk of infectious complicationsBurden of RSV diseaseOrgan transplantationRisk of infectious complicationsRespiratory syncytial virus vaccineRespiratory tract diseaseCenters for Disease Control and Prevention's Advisory CommitteeOrgan transplant recipientsSolid organ recipientsPoor clinical outcomesFood and Drug AdministrationRSV F glycoproteinRespiratory virus vaccinesRSV diseaseInfectious complicationsTransplant recipientsClinical outcomesSyncytial virusClinical decision-makingImmunocompromised individualsOrgan recipientsImmunization PracticesClinical outcomes of baloxavir versus oseltamivir in immunocompromised patients
Ringer M, Malinis M, McManus D, Davis M, Shah S, Trubin P, Topal J, Azar M. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease 2024, 26: e14249. PMID: 38319665, DOI: 10.1111/tid.14249.Peer-Reviewed Original ResearchLength of stayIntensive care unitBaloxavir groupClinical outcomesSecondary outcomesIntensive care unit length of stayRetrospective study of hospitalized patientsEfficacy of baloxavirResolution of feverImmunocompromised adult patientsStudy of hospitalized patientsRetrospective cohort studyAssociated with longer timeResolution of hypoxiaOseltamivir groupInfluenza subtypesImmunocompromised patientsInfluenza ANo significant differenceMedian timeResistance ratesNeuraminidase inhibitorsRetrospective studyBaseline characteristicsAdult patients
2023
A fast-track to fungal diagnosis: the potential of molecular diagnostics for fungi at the point of care
Trubin P, Azar M. A fast-track to fungal diagnosis: the potential of molecular diagnostics for fungi at the point of care. Expert Review Of Molecular Diagnostics 2023, 24: 143-146. PMID: 37991006, DOI: 10.1080/14737159.2023.2287504.Peer-Reviewed Original ResearchA Diagnostic Approach to Fungal Pneumonia An Infectious Diseases Perspective
Azar M. A Diagnostic Approach to Fungal Pneumonia An Infectious Diseases Perspective. CHEST Journal 2023, 165: 559-572. PMID: 37813181, DOI: 10.1016/j.chest.2023.10.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsFungal pneumoniaAppropriate diagnostic testingClinical syndromeDiagnostic testingLower respiratory tract infectionsNon-resolving pneumoniaRespiratory tract infectionsInfectious diseases perspectiveTract infectionsRadiographic patternsCommon causeEpidemiologic exposuresCorrect diagnosisRisk populationsPneumoniaDiagnostic approachHost factorsDisease perspectiveConstellation of factorsPatientsSyndromeInfectionEpidemiologyIncidenceDiagnosis
Clinical Trials
Current Trials
Kidney Transplantation in Recipients and Donors with HIV: Long Term Follow up Study
HIC ID2000030204RoleSub InvestigatorPrimary Completion Date03/31/2031Recruiting ParticipantsGenderBothAge18+ yearsHOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
HIC ID2000025220RoleSub InvestigatorPrimary Completion Date06/30/2024Recruiting ParticipantsGenderBothAge18+ yearsHOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients
HIC ID2000022391RoleSub InvestigatorPrimary Completion Date08/01/2021Recruiting ParticipantsGenderBothAge18+ yearsTrial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults (PRIOH-1)
HIC ID2000021054RoleSub InvestigatorPrimary Completion Date11/30/2023Recruiting ParticipantsGenderBothAge16+ years
Academic Achievements and Community Involvement
Clinical Care
Overview
Marwan Azar, MD, is an infectious diseases specialist with a focus on infections in patients with compromised immune systems, including organ transplant recipients and oncology patients. He has particular expertise in fungal infections, which are more common among immuno-compromised individuals.
“When I was younger, I wanted to be a biologist, studying zoology and natural ecosystems,” Dr. Azar says. “But I decided to pursue medicine because of the huge and immediate positive impact that doctors have on people’s lives. Once in medicine, I pursued both Infectious diseases and clinical microbiology, two specialties that combined my interests in human and non-human (including microbe) biology.”
Dr. Azar says some of his greatest rewards come from caring for patients, especially since infectious diseases are often curable and good treatment can usually help a patient get through a serious infection. He also enjoys helping immuno-compromised patients who may be dealing with multiple medical problems. “This kind of work is truly gratifying,” he says.
In addition, Dr. Azar is a researcher who is working on evaluating the utility of new and emerging methods to diagnose infectious diseases faster and more accurately. He is heavily involved in Yale Medicine’s response to the COVID-19 pandemic. He is a member of a Yale New Haven Health Ad Hoc COVID Treatment Team, which is made up of a wide range of specialists who are constantly evaluating the best approaches to treating infected patients.
Clinical Specialties
Fact Sheets
Powassan Virus
Learn More on Yale MedicineMpox (Formerly Monkeypox)
Learn More on Yale MedicineSepsis
Learn More on Yale MedicineCoronavirus
Learn More on Yale Medicine
Board Certifications
Medical Microbiology
- Certification Organization
- AB of Pathology
- Latest Certification Date
- 2024
- Original Certification Date
- 2017
Yale Medicine News
Links & Media
News
- May 28, 2024
Unique Case of Mucormycosis Presented in JAMA Clinical Challenge
- February 09, 2024Source: NPR
Coronavirus FAQ: I'm Immunocompromised. Will Pills, Gargles and Sprays Fend Off COVID?
- January 30, 2024
Fostering Equity and Inclusion in Infectious Diseases at Yale
- July 13, 2023
Pneumocystis Pneumonia Epidemiology, Diagnosis, Treatment & Next Steps in New Review (Discoveries & Impact July 2023)